The main aim of this study is to ascertain general satisfaction among participants with RA with day-to-day use of the Infliximab-Pen by means of a standardised participant questionnaire. In addition, it is to be investigated whether differences exist in general participant satisfaction between participant groups having different characteristics.
The primary endpoint is defined as percentage of participants that are either "very satisfied" or "satisfied" with the Remsima®-Pen.